About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Ertugliflozin
- Company
- Baylor Research Institute
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 5 recruiting
Efficacy results: Not yet reported
5 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Oct 14, 2026
Find a Clinical Trial Near Me
See recruiting studies for Ertugliflozin and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT04438213
Ertugliflozin in Chronic Heart Failure
Not yet reported Yale University 60 participants Est. completion 2025-12-30 1 site Stand-aloneHeart failureView official trial listing → -
Recruiting NCT NCT05644717
Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
Not yet reported Getz Pharma 164 participants Est. completion 2025-12-01 1 site Stand-aloneOther conditions: Liver Fat, Liver Fibrosis, Glycemic Control, Body Weight Changes, Waist Circumference, ToleranceView official trial listing → -
Recruiting NCT NCT05770687
SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
Kiyuk Chang 1000 participants Est. completion 2026-12-31 1 siteCardiovascular diseaseType 2 diabetesView official trial listing → -
Recruiting NCT NCT06580717
ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy
Not yet reported Yonsei University 200 participants Est. completion 2026-11-30 1 siteOther conditions: Nonobstructive Hypertrophic CardiomyopathyView official trial listing → -
Recruiting NCT NCT06983054
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
Not yet reported Amsterdam UMC, location VUmc 34 participants Est. completion 2025-12 2 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT00989079
A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)
Not yet reported Merck Sharp & Dohme LLC 24 participants Est. completion 2009-12-11 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01018823
A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)
Not yet reported Merck Sharp & Dohme LLC 40 participants Est. completion 2010-03-18 Stand-aloneOther conditions: Healthy VolunteerView official trial listing → -
Completed NCT NCT01054300
Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)
Not yet reported Merck Sharp & Dohme LLC 52 participants Est. completion 2010-04-07 Stand-aloneType 2 diabetes Other conditions: AdultView official trial listing → -
Completed NCT NCT01059825
Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)
Not yet reported Merck Sharp & Dohme LLC 375 participants Est. completion 2011-01-20 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01096667
Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)
Not yet reported Merck Sharp & Dohme LLC 194 participants Est. completion 2011-02-25 Stand-aloneType 2 diabetes Other conditions: HypertensionView official trial listing → -
Completed NCT NCT01114568
Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)
Not yet reported Merck Sharp & Dohme LLC 12 participants Est. completion 2010-06 Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT01127308
A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)
Not yet reported Merck Sharp & Dohme LLC 6 participants Est. completion 2010-07 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01223339
Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)
Not yet reported Merck Sharp & Dohme LLC 24 participants Est. completion 2011-02 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01948986
Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)
Not yet reported Merck Sharp & Dohme LLC 36 participants Est. completion 2014-10-16 Stand-aloneType 2 diabetes Other conditions: Renal ImpairmentView official trial listing → -
Completed NCT NCT01958671
A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
Not yet reported Merck Sharp & Dohme LLC 461 participants Est. completion 2016-07-28 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01986855
A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
Not yet reported Merck Sharp & Dohme LLC 468 participants Est. completion 2016-09-28 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01986881
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Not yet reported Merck Sharp & Dohme LLC 8246 participants Est. completion 2019-12-27 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01999218
Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
Not yet reported Merck Sharp & Dohme LLC 1326 participants Est. completion 2017-04-18 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02033889
A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
Not yet reported Merck Sharp & Dohme LLC 621 participants Est. completion 2017-08-03 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02036515
Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
Not yet reported Merck Sharp & Dohme LLC 464 participants Est. completion 2016-06-06 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02099110
Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
Not yet reported Merck Sharp & Dohme LLC 1233 participants Est. completion 2016-05-26 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02115347
Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)
Not yet reported Merck Sharp & Dohme LLC 16 participants Est. completion 2015-01-19 Stand-aloneType 2 diabetes Other conditions: Hepatic ImpairmentView official trial listing → -
Completed NCT NCT02226003
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
Not yet reported Merck Sharp & Dohme LLC 291 participants Est. completion 2016-02-23 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02411929
A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)
Not yet reported Merck Sharp & Dohme LLC 8 participants Est. completion 2015-02-09 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02630706
A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)
Not yet reported Merck Sharp & Dohme LLC 506 participants Est. completion 2017-12-27 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03416270
ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure
Not yet reported University Health Network, Toronto 34 participants Est. completion 2021-04-14 3 sites Stand-aloneType 2 diabetesHeart failureView official trial listing → -
Withdrawn NCT NCT03640221
Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.
Not yet reported Cedars-Sinai Medical Center Est. completion 2020-08-31 1 site Stand-aloneType 2 diabetes Other conditions: HypertensionView official trial listing → -
Completed NCT NCT03717194
Effect of Ertugliflozin on Cardiac Function in Diabetes
Not yet reported Soo Lim 102 participants Est. completion 2023-04-30 1 site Stand-aloneType 2 diabetesHeart failureView official trial listing → -
Withdrawn NCT NCT03813316
Approaches To Therapy Escalation In T2D
Not yet reported LMC Diabetes & Endocrinology Ltd. Est. completion 2019-09-18 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT04027530
Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.
Not yet reported Amsterdam UMC, location VUmc 40 participants Est. completion 2023-01-09 1 site Stand-aloneType 2 diabetesChronic kidney disease Other conditions: Renal Hypoxia, Renoprotection, SGLT2 Inhibitor, ErtugliflozinView official trial listing → -
Completed NCT NCT04029480
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
Not yet reported Merck Sharp & Dohme LLC 166 participants Est. completion 2025-04-11 104 sites Stand-aloneType 2 diabetesView official trial listing → -
Terminated NCT NCT04071626
Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure
Not yet reported University Hospitals Cleveland Medical Center 9 participants Est. completion 2023-01-11 1 site Stand-aloneHeart failureType 2 diabetesView official trial listing → -
Completed NCT NCT04167761
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
Not yet reported Stanford University 61 participants Est. completion 2023-12-31 1 site Stand-aloneCardiovascular diseaseType 2 diabetes Other conditions: Atherosclerosis, Insulin ResistanceView official trial listing → -
Completed NCT NCT04231331
Ertugliflozin for Functional Mitral Regurgitation
Not yet reported Asan Medical Center 128 participants Est. completion 2023-11-15 3 sitesOther conditions: Mitral Valve Insufficiency, Left Ventricular Systolic DysfunctionView official trial listing → -
Status unknown NCT NCT04490681
Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL)
Not yet reported Yonsei University 52 participants Est. completion 2022-12 1 site Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT04505774
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
Not yet reported Matthew Neal MD 3591 participants Est. completion 2024-01-26 101 sitesOther conditions: Covid19View official trial listing → -
Terminated NCT NCT04600921
Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study
Not yet reported Medical University of Graz 55 participants Est. completion 2023-10-18 8 sitesHeart failure Other conditions: Implantable Cardioverter-Defibrillators, Cardiac Resynchronization TherapyView official trial listing → -
Completed NCT NCT05152940
ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF
Not yet reported Icahn School of Medicine at Mount Sinai 28 participants Est. completion 2023-10-27 1 siteHeart failure Other conditions: CongestionView official trial listing → -
Status unknown NCT NCT05161429
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
Brigham and Women's Hospital 550000 participants Est. completion 2024-06-30 5 sitesType 2 diabetesView official trial listing → -
Active, not recruiting NCT NCT05220917
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Brigham and Women's Hospital 781430 participants Est. completion 2027-09-30 1 siteType 2 diabetes Other conditions: Cardiovascular Events, Renal DiseaseView official trial listing → -
Status unknown NCT NCT05477017
Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients
University of Milan 800 participants Est. completion 2023-03 1 siteOther conditions: Type2DiabetesView official trial listing → -
Completed NCT NCT05556291
Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study
Getz Pharma 190 participants Est. completion 2024-12-01 3 sitesOther conditions: Efficacy, Safety, TolerabilityView official trial listing → -
Active, not recruiting NCT NCT05662865
Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers
Not yet reported AdventHealth Translational Research Institute 9 participants Est. completion 2026-12 1 siteOther conditions: Ketones, MetabolismView official trial listing → -
Completed NCT NCT05727579
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study
Not yet reported Amsterdam UMC, location VUmc 41 participants Est. completion 2025-11-30 1 siteChronic kidney disease Other conditions: Diabetes Mellitus, HypertensionView official trial listing → -
Status unknown NCT NCT06449235
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
Not yet reported Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders 938 participants Est. completion 2025-06 1 siteOther conditions: Type2diabetesView official trial listing → -
Active, not recruiting NCT NCT07188545
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Ohio State University 23280000 participants Est. completion 2029-06-30 1 siteMetabolic syndromeView official trial listing → -
Completed NCT NCT07266779
Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets and Reference Product (R) of Segluromet 7.5 mg/ 1000 mg Film Coated Tablets in Healthy, Adult, Human Subjects Under Fed Condition.
Not yet reported Humanis Saglık Anonim Sirketi 36 participants Est. completion 2025-10-11 1 site Stand-aloneType 2 diabetesView official trial listing → -
Enrolling by invitation NCT NCT07547878
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
Not yet reported Baylor Research Institute 64 participants Est. completion 2029-03-31 1 siteChronic kidney diseaseType 2 diabetesView official trial listing → -
Not yet recruiting NCT NCT07621380
Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial Infarction
Not yet reported Shanghai Zhongshan Hospital 476 participants Est. completion 2028-03-01 1 site Stand-aloneType 2 diabetesCardiovascular diseaseView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Also known as: Ertugliflozin, SEGLUROMET, STEGLUJAN, STEGLATRO
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.